First Deals for High-Speed Screening of Ion Channel Drug Targets - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
First Deals for High-Speed Screening of Ion Channel Drug Targets


First Deals for High-Speed Screening of Ion Channel Drug Targets

PR Newswire

BALLERUP, Denmark, May 14, 2014 /PRNewswire/ --


Sophion Bioscience ( sophion.com ), part of Biolin Scientific, has received its first purchase orders for its new high throughput screening platform from leading pharma companies. The Sophion Qube™ measures the effect of potential new drug candidates directly on ion channels in living cells. By a unique combination of high quality recordings and high throughput, the Sophion Qube can boost the productivity of the first phases of ion channel drug discovery dramatically.

Qube is a 384-channel automatic patch clamp system that delivers ion channel data at an unprecedented throughput.  At full integration into an existing screening line, Sophion Qube has the capacity to test more than 30,000 compounds in 24 hours. For up to 4 hours unattended operations, Sophion Qube is also available as a stand-alone system.

Sophion Qube is designed to reduce development time of drugs targeting ion channels, for indications like pain, epilepsy, bipolar disorder, depression and cystic fibrosis.

Morten Sunesen, VP of Drug Discovery Systems at Biolin Scientific, commented: "I am very happy to see that the most prestigious ion-channel laboratories in the world have chosen Sophion Qube. It's a solid proof of our concept of uniting manual patch clamp quality with high throughput. Sophion Qube delivers a torrent of information for characterizing ion channels. Instead of screening on secondary information, we're getting direct measurement at the point of action. That's highly valuable for an evidence-based approach in drug discovery, and can greatly enhance the way ion channel drug discovery works".

About Biolin Scientific 

Biolin Scientific is a leading Nordic instrumentation company with revenues of SEK 240 million. Our premium solutions help the pharmaceutical industry to discover new drugs and treatments. Companies working with energy, chemicals and advanced materials use our technologies for material characterization and quality control. Our precision instruments support academic research institutes in their studies of the frontiers of science and technology.

Biolin Scientific proprietary systems are based on nanotechnology and advanced measurement techniques, which have earned leadership in several industries through their commitment to scientific excellence and continuous product development. Our commitment to customer service and application support is a key feature of our operations. We focus on working together with customers and building long-lasting relations. Today, Biolin Scientific provides products and services in more than 70 countries around the world. Our portfolio consists of the following brands: Attension, (attension.com), KSV NIMA (ksvnima.com), Q-Sense (qsense.com) and Sophion (sophion.com).

Contact: Morten Sunesen, VP of global sales and Customer support, +45-40334205


SOURCE Biolin Scientific AB

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here